To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Certolizumab pegol
Certolizumab pegol (CDP870) (proposed tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Additional recommended knowledgeIt is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2] Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease. In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents. References
|
||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Certolizumab_pegol". A list of authors is available in Wikipedia. |
- Honeywell Sells Novel Low-Global-Warming Blowing Agent to European Customers - Product used in energy-saving foam to seal around windows and doors, as well as in foam adhesives and aerosols, meets EU global warming regulatory requirements
- Elemental Analysis of Sodium Ion Battery Cathode Materials by Agilent ICP-OES
- Altuglas International increase prices for its acrylic sheet and blocks
- Carbohydrate_metabolism